Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBITDA Margin (2022 - 2026)

bioAffinity Technologies has reported EBITDA Margin over the past 5 years, most recently at 265.82% for Q1 2026.

  • Quarterly EBITDA Margin fell 12644.0% to 265.82% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 201.62% through Mar 2026, down 9414.0% year-over-year, with the annual reading at 168.81% for FY2025, 7491.0% down from the prior year.
  • EBITDA Margin was 265.82% for Q1 2026 at bioAffinity Technologies, down from 194.59% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 79.22% in Q1 2024 and troughed at 166806.19% in Q1 2023.
  • The 5-year median for EBITDA Margin is 194.62% (2025), against an average of 23999.31%.
  • Year-over-year, EBITDA Margin soared 16672697bps in 2024 and then crashed -12644bps in 2026.
  • A 5-year view of EBITDA Margin shows it stood at 68902.77% in 2022, then surged by 100bps to 98.32% in 2023, then plummeted by -34bps to 131.53% in 2024, then plummeted by -48bps to 194.59% in 2025, then crashed by -37bps to 265.82% in 2026.
  • Per Business Quant, the three most recent readings for BIAF's EBITDA Margin are 265.82% (Q1 2026), 194.59% (Q4 2025), and 155.47% (Q3 2025).